Myeloperoxidase: a potential therapeutic target for coronary artery disease

References

• Benjamin EJ, Virani SS, Callaway CW, et al. Heart disease and stroke statistics—2018 update: a report from the american heart association. Circulation. 2018;137(12):e67–e492.
   PubMed Web of Science ®Google Scholar
• Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;352(16):1685–1695.
   PubMed Web of Science ®Google Scholar
• Libby P, Loscalzo J, Ridker PM, et al. Inflammation, immunity, and infection in atherothrombosis: JACC review topic of the week. J Am Coll Cardiol. 2018 Oct 23;72(17):2071–2081.
   PubMed Web of Science ®Google Scholar
• van der Wal AC, Becker AE, van der Loos CM, et al. Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology. Circulation. 1994;89(1):36–44.
   PubMed Web of Science ®Google Scholar
• Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017;377(12):1119–1131.
   PubMed Web of Science ®Google Scholar
• Koeth RA, Haselden V, Tang WH. Myeloperoxidase in cardiovascular disease. Adv Clin Chem. 2013;62:1–32.
   PubMed Web of Science ®Google Scholar
• Brennan ML, Penn MS, Van Lente F, et al. Prognostic value of myeloperoxidase in patients with chest pain. N Engl J Med. 2003;349(17):1595–1604.
   PubMed Web of Science ®Google Scholar
• Morrow DA, Sabatine MS, Brennan ML, et al. Concurrent evaluation of novel cardiac biomarkers in acute coronary syndrome: myeloperoxidase and soluble CD40 ligand and the risk of recurrent ischaemic events in TACTICS-TIMI 18. Eur Heart J. 2008;29(9):1096–1102.
   PubMed Web of Science ®Google Scholar
• Zhang R, Brennan ML, Fu X, et al. Association between myeloperoxidase levels and risk of coronary artery disease. Jama. 2001;286(17):2136–2142.
   PubMed Web of Science ®Google Scholar
• Meuwese MC, Stroes ES, Hazen SL, et al. Serum myeloperoxidase levels are associated with the future risk of coronary artery disease in apparently healthy individuals: the EPIC-Norfolk prospective population study. J Am Coll Cardiol. 2007;50(2):159–165.
   PubMed Web of Science ®Google Scholar
• Ali M, Pulli B, Courties G, et al. Myeloperoxidase inhibition improves ventricular function and remodeling after experimental myocardial infarction. JACC. 2016;1(7):633–643.
   Google Scholar
• Cheng D, Talib J, Stanley Christopher P, et al. Inhibition of MPO (Myeloperoxidase) attenuates endothelial dysfunction in mouse models of vascular inflammation and atherosclerosis. Arterioscler Thromb Vasc Biol. 2019 Jul 01;39(7):1448–1457.
   PubMed Web of Science ®Google Scholar
• Teng N, Maghzal GJ, Talib J, et al. The roles of myeloperoxidase in coronary artery disease and its potential implication in plaque rupture. Redox Rep. 2017;22(2):51–73.
   PubMed Web of Science ®Google Scholar
• Khan AA, Alsahli MA, Rahmani AH. Myeloperoxidase as an active disease biomarker: recent biochemical and pathological perspectives. Med Sci (Basel). 2018;6(2):33.
   Google Scholar
• Koeffler HP, Ranyard J, Pertcheck M. Myeloperoxidase: its structure and expression during myeloid differentiation. Blood. 1985;65(2):484–491.
   PubMed Web of Science ®Google Scholar
• Swirski FK, Wildgruber M, Ueno T, et al. Myeloperoxidase-rich Ly-6C+ myeloid cells infiltrate allografts and contribute to an imaging signature of organ rejection in mice. J Clin Invest. 2010;120(7):2627–2634.
   PubMed Web of Science ®Google Scholar
• Olsson I, Persson AM, Stromberg K. Biosynthesis, transport and processing of myeloperoxidase in the human leukaemic promyelocytic cell line HL-60 and normal marrow cells. Biochem J. 1984;223(3):911–920.
   PubMed Web of Science ®Google Scholar
• Hansson M, Olsson I, Nauseef WM. Biosynthesis, processing, and sorting of human myeloperoxidase. Arch Biochem Biophys. 2006;445(2):214–224.
   PubMed Web of Science ®Google Scholar
• Nicholls SJ, Hazen SL. Myeloperoxidase and cardiovascular disease. Arterioscler Thromb Vasc Biol. 2005;25(6):1102–1111.
   PubMed Web of Science ®Google Scholar
• Nussbaum C, Klinke A, Adam M, et al. Myeloperoxidase: a leukocyte-derived protagonist of inflammation and cardiovascular disease. Antioxid Redox Signal. 2012 Feb 20;18(6):692–713.
   PubMed Web of Science ®Google Scholar
• Nauseef WM. Biosynthesis of human myeloperoxidase. Arch Biochem Biophys. 2018;642:1–9.
   PubMed Web of Science ®Google Scholar
• Kumar AP, Piedrafita FJ, Reynolds WF. Peroxisome proliferator-activated receptor gamma ligands regulate myeloperoxidase expression in macrophages by an estrogen-dependent mechanism involving the −463GA promoter polymorphism. J Biol Chem. 2004;279(9):8300–8315.
   PubMed Web of Science ®Google Scholar
• Kettle AJ, Winterbourn CC. Myeloperoxidase: a key regulator of neutrophil oxidant production. Redox Rep. 1997 Feb 01;3(1):3–15.
   PubMed Web of Science ®Google Scholar
• Klebanoff SJ. Myeloperoxidase: friend and foe. J Leukoc Biol. 2005;77(5):598–625.
   PubMed Web of Science ®Google Scholar
• Podrez EA, Abu-Soud HM, Hazen SL. Myeloperoxidase-generated oxidants and atherosclerosis. Free Radic Biol Med. 2000 Jun 15;28(12):1717–1725.
   PubMed Web of Science ®Google Scholar
• Winterbourn CC, Hampton MB, Livesey JH, et al. Modeling the reactions of superoxide and myeloperoxidase in the neutrophil phagosome: implications for microbial killing. J Biol Chem. 2006;281(52):39860–39869.
   PubMed Web of Science ®Google Scholar
• Prütz WA. Hypochlorous acid interactions with thiols, nucleotides, DNA, and other biological substrates. Arch Biochem Biophys. 1996 Aug 01;332(1):110–120.
   PubMed Web of Science ®Google Scholar
• Fuchs B, Schiller J. Glycosaminoglycan degradation by selected reactive oxygen species. Antioxid Redox Signal. 2013 Sep 01;21(7):1044–1062.
   Web of Science ®Google Scholar
• Kubala L, Kolářová H, Víteček J, et al. The potentiation of myeloperoxidase activity by the glycosaminoglycan-dependent binding of myeloperoxidase to proteins of the extracellular matrix. Biochim Biophys Acta Gen Subj. 2013 Oct 01;1830(10):4524–4536.
   Web of Science ®Google Scholar
• Hazen SL, Heinecke JW. 3-Chlorotyrosine, a specific marker of myeloperoxidase-catalyzed oxidation, is markedly elevated in low density lipoprotein isolated from human atherosclerotic intima. J Clin Invest. 1997;99(9):2075–2081.
   PubMed Web of Science ®Google Scholar
• Takeshita J, Byun J, Nhan TQ, et al. Myeloperoxidase generates 5-chlorouracil in human atherosclerotic tissue: a potential pathway for somatic mutagenesis by macrophages. J Biol Chem. 2006;281(6):3096–3104.
   PubMed Web of Science ®Google Scholar
• Hazell LJ, Arnold L, Flowers D, et al. Presence of hypochlorite-modified proteins in human atherosclerotic lesions. J Clin Invest. 1996;97(6):1535–1544.
   PubMed Web of Science ®Google Scholar
• Hawkins CL, Davies MJ. Detection, identification, and quantification of oxidative protein modifications. J Biol Chem. 2019;294(51):19683–19708.
   PubMed Web of Science ®Google Scholar
• Savenkova MI, Mueller DM, Heinecke JW. Tyrosyl radical generated by myeloperoxidase is a physiological catalyst for the initiation of lipid peroxidation in low density lipoprotein. J Biol Chem. 1994;269(32):20394–20400.
   PubMed Web of Science ®Google Scholar
• Jacob JS, Cistola DP, Hsu FF, et al. Human phagocytes employ the myeloperoxidase-hydrogen peroxide system to synthesize dityrosine, trityrosine, pulcherosine, and isodityrosine by a tyrosyl radical-dependent pathway. J Biol Chem. 1996;271(33):19950–19956.
   PubMed Web of Science ®Google Scholar
• Podrez EA, Schmitt D, Hoff HF, et al. Myeloperoxidase-generated reactive nitrogen species convert LDL into an atherogenic form in vitro. J Clin Investig. 1999;103(11):1547–1560.
   PubMed Web of Science ®Google Scholar
• Eiserich JP, Hristova M, Cross CE, et al. Formation of nitric oxide-derived inflammatory oxidants by myeloperoxidase in neutrophils. Nature. 1998;391(6665):393–397.
   PubMed Web of Science ®Google Scholar
• Hazen SL, Zhang R, Shen Z, et al. Formation of nitric oxide-derived oxidants by myeloperoxidase in monocytes pathways for monocyte-mediated protein nitration and lipid peroxidation in vivo. Circ Res. 1999;85(10):950–958.
   PubMed Web of Science ®Google Scholar
• van Dalen CJ, Whitehouse MW, Winterbourn CC, et al. Thiocyanate and chloride as competing substrates for myeloperoxidase. Biochem J. 1997;327(Pt 2):487–492.
   PubMedGoogle Scholar
• Wang Z, Nicholls SJ, Rodriguez ER, et al. Protein carbamylation links inflammation, smoking, uremia and atherogenesis. Nat Med. 2007;13:1176.
   PubMed Web of Science ®Google Scholar
• Daugherty A, Dunn JL, Rateri DL, et al. Myeloperoxidase, a catalyst for lipoprotein oxidation, is expressed in human atherosclerotic lesions. J Clin Invest. 1994;94(1):437–444.
   PubMed Web of Science ®Google Scholar
• Sugiyama S, Okada Y, Sukhova GK, et al. Macrophage myeloperoxidase regulation by granulocyte macrophage colony-stimulating factor in human atherosclerosis and implications in acute coronary syndromes. Am J Pathol. 2001;158(3):879–891.
   PubMed Web of Science ®Google Scholar
• Kutter D, Devaquet P, Vanderstocken G, et al. Consequences of total and subtotal myeloperoxidase deficiency: risk or benefit? Acta Haematol. 2000;104(1):10–15.
   PubMed Web of Science ®Google Scholar
• Asselbergs FW, Reynolds WF, Cohen-Tervaert JW, et al. Myeloperoxidase polymorphism related to cardiovascular events in coronary artery disease. Am J Med. 2004 Mar 15;116(6):429–430.
   PubMed Web of Science ®Google Scholar
• Brennan ML, Anderson MM, Shih DM, et al. Increased atherosclerosis in myeloperoxidase-deficient mice. J Clin Invest. 2001;107(4):419–430.
   PubMed Web of Science ®Google Scholar
• McMillen TS, Heinecke JW, LeBoeuf RC. Expression of human myeloperoxidase by macrophages promotes atherosclerosis in mice. Circulation. 2005;111(21):2798–2804.
   PubMed Web of Science ®Google Scholar
• Aratani Y. Myeloperoxidase: its role for host defense, inflammation, and neutrophil function. Arch Biochem Biophys. 2018;640:47–52.
   PubMed Web of Science ®Google Scholar
• Michos ED, McEvoy JW, Blumenthal RS. Lipid management for the prevention of atherosclerotic cardiovascular disease. N Engl J Med. 2019;381(16):1557–1567.
   PubMed Web of Science ®Google Scholar
• Hazell LJ, Stocker R. Oxidation of low-density lipoprotein with hypochlorite causes transformation of the lipoprotein into a high-uptake form for macrophages. Biochem J. 1993;290(Pt 1):165–172.
   PubMedGoogle Scholar
• Hazell LJ, van den Berg JJM, Stocker R. Oxidation of low-density lipoprotein by hypochlorite causes aggregation that is mediated by modification of lysine residues rather than lipid oxidation. Biochem J. 1994;302(1):297–304.
   PubMedGoogle Scholar
• Malle E, Marsche G, Arnhold J, et al. Modification of low-density lipoprotein by myeloperoxidase-derived oxidants and reagent hypochlorous acid. Biochim Biophys Acta. 2006;1761(4):392–415.
   PubMed Web of Science ®Google Scholar
• Podrez EA, Febbraio M, Sheibani N, et al. Macrophage scavenger receptor CD36 is the major receptor for LDL modified by monocyte-generated reactive nitrogen species. J Clin Investig. 2000;105(8):1095–1108.
   PubMed Web of Science ®Google Scholar
• Steffen Y, Schewe T, Sies H. Epicatechin protects endothelial cells against oxidized LDL and maintains NO synthase. Biochem Biophys Res Commun. 2005 Jun 17;331(4):1277–1283.
   PubMed Web of Science ®Google Scholar
• Vicca S, Massy ZA, Hennequin C, et al. Apoptotic pathways involved in U937 cells exposed to LDL oxidized by hypochlorous acid. Free Radic Biol Med. 2003 Sep 15;35(6):603–615.
   PubMed Web of Science ®Google Scholar
• de la Llera-moya M, Drazul-Schrader D, Asztalos BF, et al. The ability to promote efflux via ABCA1 determines the capacity of serum specimens with similar high-density lipoprotein cholesterol to remove cholesterol from macrophages. Arterioscler Thromb Vasc Biol. 2010;30(4):796–801.
   PubMed Web of Science ®Google Scholar
• Rosenson RS, Brewer HB Jr., Ansell BJ, et al. Dysfunctional HDL and atherosclerotic cardiovascular disease. Nat Rev Cardiol. 2016;13(1):48–60.
   PubMed Web of Science ®Google Scholar
• Zheng L, Nukuna B, Brennan ML, et al. Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and function impairment in subjects with cardiovascular disease. J Clin Investig. 2004;114(4):529–541.
   PubMed Web of Science ®Google Scholar
• Zheng L, Settle M, Brubaker G, et al. Localization of nitration and chlorination sites on apolipoprotein A-I catalysed by myeloperoxidase in human atheroma and associated oxidative impairment in ABCA1-dependent cholesterol efflux from macrophages. J Biol Chem. 2005;280(1):38–47.
   PubMed Web of Science ®Google Scholar
• Huang Y, Wu Z, Riwanto M, et al. Myeloperoxidase, paraoxonase-1, and HDL form a functional ternary complex. J Clin Invest. 2013;123(9):3815–3828.
   PubMed Web of Science ®Google Scholar
• Shao B, Cavigiolio G, Brot N, et al. Methionine oxidation impairs reverse cholesterol transport by apolipoprotein A-I. Proc Nat Acad Sci. 2008;105(34):12224.
   PubMed Web of Science ®Google Scholar
• Smith JD. Myeloperoxidase, inflammation, and dysfunctional high-density lipoprotein. J Clin Lipidol. 2010 Sep-Oct;4(5):382–388.
   PubMed Web of Science ®Google Scholar
• Peng DQ, Brubaker G, Wu Z, et al. Apolipoprotein A-I tryptophan substitution leads to resistance to myeloperoxidase-mediated loss of function. Arterioscler Thromb Vasc Biol. 2008;28(11):2063–2070.
   PubMed Web of Science ®Google Scholar
• Marsche G, Hammer A, Oskolkova O, et al. Hypochlorite-modified high density lipoprotein, a high affinity ligand to scavenger receptor class B, type I, impairs high density lipoprotein-dependent selective lipid uptake and reverse cholesterol transport. J Biol Chem. 2002;277(35):32172–32179.
   PubMed Web of Science ®Google Scholar
• Zhang C, Reiter C, Eiserich JP, et al. L-arginine chlorination products inhibit endothelial nitric oxide production. J Biol Chem. 2001;276(29):27159–27165.
   PubMed Web of Science ®Google Scholar
• Stocker R, Huang A, Jeranian E, et al. Hypochlorous acid impairs endothelium-derived nitric oxide bioactivity through a superoxide-dependent mechanism. Arterioscler Thromb Vasc Biol. 2004;24(11):2028–2033.
   PubMed Web of Science ®Google Scholar
• Marsche G, Heller R, Fauler G, et al. 2-Chlorohexadecanal derived from hypochlorite-modified high-density lipoprotein - Associated plasmalogen is a natural inhibitor of endothelial nitric oxide biosynthesis. Arterioscler Thromb Vasc Biol. 2004;24(12):2302–2306.
   PubMed Web of Science ®Google Scholar
• Vita JA, Brennan ML, Gokce N, et al. Serum myeloperoxidase levels independently predict endothelial dysfunction in humans. Circulation. 2004;110(9):1134–1139.
   PubMed Web of Science ®Google Scholar
• Baldus S, Heitzer T, Eiserich JP, et al. Myeloperoxidase enhances nitric oxide catabolism during myocardial ischemia and reperfusion. Free Radic Biol Med. 2004;37(6):902–911.
   PubMed Web of Science ®Google Scholar
• Yunoki K, Naruko T, Komatsu R, et al. Relation of elevated levels of plasma myeloperoxidase to impaired myocardial microcirculation after reperfusion in patients with acute myocardial infarction. Am J Cardiol. 2010 Apr 01;105(7):922–929.
   PubMed Web of Science ®Google Scholar
• Narula J, Nakano M, Virmani R, et al. Histopathologic characteristics of atherosclerotic coronary disease and implications of the findings for the invasive and noninvasive detection of vulnerable plaques. J Am Coll Cardiol. 2013;61(10):1041–1051.
   PubMed Web of Science ®Google Scholar
• Sugiyama S, Kugiyama K, Aikawa M, et al. Hypochlorous acid, a macrophage product, induces endothelial apoptosis and tissue factor expression. Arterioscler Thromb Vasc Biol. 2004;24(7):1309–1314.
   PubMed Web of Science ®Google Scholar
• Fu X, Kassim SY, Parks WC, et al. Hypochlorous acid oxygenates the cysteine switch domain of pro-matrilysin (MMP-7). A mechanism for matrix metalloproteinase activation and atherosclerotic plaque rupture by myeloperoxidase. J Biol Chem. 2001;276(44):41279–41287.
   PubMed Web of Science ®Google Scholar
• Silvestre-Roig C, Winther M, Weber C, et al. Atherosclerotic plaque destabilization. Circ Res. 2014;114(1):214–226.
   PubMed Web of Science ®Google Scholar
• Bennett MR, Sinha S, Owens GK. Vascular smooth muscle cells in atherosclerosis. Circ Res. 2016;118(4):692–702.
   PubMed Web of Science ®Google Scholar
• Cai H, Chuang CY, Vanichkitrungruang S, et al. Hypochlorous acid-modified extracellular matrix contributes to the behavioral switching of human coronary artery smooth muscle cells. Free Radic Biol Med. 2019 Apr 01;134:516–526.
   PubMed Web of Science ®Google Scholar
• Vanichkitrungruang S, Chuang CY, Hawkins CL, et al. Oxidation of human plasma fibronectin by inflammatory oxidants perturbs endothelial cell function. Free Radic Biol Med. 2019 May 20;136:118–134.
   PubMed Web of Science ®Google Scholar
• Wang Y, Rosen H, Madtes DK, et al. Myeloperoxidase inactivates TIMP-1 by oxidizing its N-terminal cysteine residue: an oxidative mechanism for regulating proteolysis during inflammation. J Biol Chem. 2007;282(44):31826–31834.
   PubMed Web of Science ®Google Scholar
• Tabas I. Macrophage apoptosis in atherosclerosis: consequences on plaque progression and the role of endoplasmic reticulum stress. Antioxid Redox Signal. 2009;11(9):2333–2339.
   PubMed Web of Science ®Google Scholar
• Doring Y, Soehnlein O, Weber C. Neutrophil extracellular traps in atherosclerosis and atherothrombosis. Circ Res. 2017;120(4):736–743.
   PubMed Web of Science ®Google Scholar
• Papayannopoulos V, Metzler KD, Hakkim A, et al. Neutrophil elastase and myeloperoxidase regulate the formation of neutrophil extracellular traps. J Cell Biol. 2010;191(3):677–691.
   PubMed Web of Science ®Google Scholar
• Borissoff JI, Joosen IA, Versteylen MO, et al. Elevated levels of circulating DNA and chromatin are independently associated with severe coronary atherosclerosis and a prothrombotic state. Arterioscler Thromb Vasc Biol. 2013;33(8):2032–2040.
   PubMed Web of Science ®Google Scholar
• Ndrepepa G. Myeloperoxidase - A bridge linking inflammation and oxidative stress with cardiovascular disease. Clin Chim Acta. 2019;493:36–51.
   PubMed Web of Science ®Google Scholar
• Kettle AJ, Gedye CA, Hampton MB, et al. Inhibition of myeloperoxidase by benzoic acid hydrazides. Biochem J. 1995;308(Pt 2):559–563.
   PubMedGoogle Scholar
• Kettle AJ, Gedye CA, Winterbourn CC. Mechanism of inactivation of myeloperoxidase by 4-aminobenzoic acid hydrazide. Biochem J. 1997;321(Pt 2):503–508.
   PubMedGoogle Scholar
• Galijasevic S. The development of myeloperoxidase inhibitors. Bioorg Med Chem Lett. 2019;29(1):1–7.
   PubMed Web of Science ®Google Scholar
• Han L, Shen X, Pan L, et al. Aminobenzoic acid hydrazide, a myeloperoxidase inhibitor, alters the adhesive properties of neutrophils isolated from acute myocardial infarction patients. Heart Vessels. 2012 Sep 01;27(5):468–474.
   PubMed Web of Science ®Google Scholar
• Tiyerili V, Camara B, Becher MU, et al. Neutrophil-derived myeloperoxidase promotes atherogenesis and neointima formation in mice. Int J Cardiol. 2016 Feb 01;204:29–36.
   PubMed Web of Science ®Google Scholar
• Kettle AJ, Gedye CA, Winterbourn CC. Superoxide is an antagonist of anti-inflammatory drugs that inhibit hypochlorous acid production by myeloperoxidase. Biochem Pharmacol. 1993 Apr 25;45(10):2003–2010.
   PubMed Web of Science ®Google Scholar
• Kato Y, Nagao A, Terao J, et al. Inhibition of myeloperoxidase-catalyzed tyrosylation by phenolic antioxidants in vitro. Biosci Biotechnol Biochem. 2003;67(5):1136–1139.
   PubMed Web of Science ®Google Scholar
• Liu C, Desikan R, Ying Z, et al. Effects of a novel pharmacologic inhibitor of myeloperoxidase in a mouse atherosclerosis model. Plos One. 2012;7(12):e50767–e67.
   PubMed Web of Science ®Google Scholar
• Cooper DS. Antithyroid Drugs. N Engl J Med. 2005;352(9):905–917.
   PubMed Web of Science ®Google Scholar
• Lee E, Hirouchi M, Hosokawa M, et al. Inactivation of peroxidases of rat bone marrow by repeated administration of propylthiouracil is accompanied by a change in the heme structure. Biochem Pharmacol. 1988;37(11):2151–2153.
   PubMed Web of Science ®Google Scholar
• Ruggeri RB, Buckbinder L, Bagley SW, et al. Discovery of 2-(6-(5-Chloro-2-methoxyphenyl)-4-oxo-2-thioxo-3,4-dihydropyrimidin-1(2H)-yl)acet amide (PF-06282999): a highly selective mechanism-based myeloperoxidase inhibitor for the treatment of cardiovascular diseases. J Med Chem. 2015;58(21):8513–8528.
   PubMed Web of Science ®Google Scholar
• Dong JQ, Varma MV, Wolford A, et al. Pharmacokinetics and disposition of the thiouracil derivative PF-06282999, an orally bioavailable, irreversible inactivator of myeloperoxidase enzyme, across animals and humans. Drug Metab Dispos. 2016;44(2):209–219.
   PubMed Web of Science ®Google Scholar
• Roth Flach RJ, Su C, Bollinger E, et al. Myeloperoxidase inhibition in mice alters atherosclerotic lesion composition. Plos One. 2019;14(3):e0214150.
   PubMed Web of Science ®Google Scholar
• Li T, Jiang S, Ni B, et al. Discontinued drugs for the treatment of cardiovascular disease from 2016 to 2018. Int J Mol Sci. 2019;20(18):4513.
   Web of Science ®Google Scholar
• Tiden AK, Sjogren T, Svensson M, et al. 2-thioxanthines are mechanism-based inactivators of myeloperoxidase that block oxidative stress during inflammation. J Biol Chem. 2011;286(43):37578–37589.
   PubMed Web of Science ®Google Scholar
• Björnsdottir H, Welin A, Michaëlsson E, et al. Neutrophil NET formation is regulated from the inside by myeloperoxidase-processed reactive oxygen species. Free Radic Biol Med. 2015 Dec 01;89:1024–1035.
   PubMed Web of Science ®Google Scholar
• Rashid I, Maghzal GJ, Chen YC, et al. Myeloperoxidase is a potential molecular imaging and therapeutic target for the identification and stabilization of high-risk atherosclerotic plaque. Eur Heart J. 2018;39(35):3301–3310.
   PubMed Web of Science ®Google Scholar
• Maghzal GJ, Cergol KM, Shengule SR, et al. Assessment of myeloperoxidase activity by the conversion of hydroethidine to 2-chloroethidium. J Biol Chem. 2014;289(9):5580–5595.
   PubMed Web of Science ®Google Scholar
• Duclos F, Abell LM, Harden DG, et al. Triazolopyrimidines identified as reversible myeloperoxidase inhibitors. MedChemComm. 2017;8(11):2093–2099.
   PubMed Web of Science ®Google Scholar
• Koelsch M, Mallak R, Graham GG, et al. Acetaminophen (paracetamol) inhibits myeloperoxidase-catalyzed oxidant production and biological damage at therapeutically achievable concentrations. Biochem Pharmacol. 2010;79(8):1156–1164.
   PubMed Web of Science ®Google Scholar
• Marquez LA, Dunford HB. Interaction of acetaminophen with myeloperoxidase intermediates: optimum stimulation of enzyme activity. Arch Biochem Biophys. 1993 Sep 01;305(2):414–420.
   PubMed Web of Science ®Google Scholar
• Van Zyl JM, Basson K, Van Der Walt BJ. The inhibitory effect of acetaminophen on the myeloperoxidase-induced antimicrobial system of the polymorphonuclear leukocyte. Biochem Pharmacol. 1989 Jan 01;38(1):161–165.
   PubMed Web of Science ®Google Scholar
• Nenseter MS, Halvorsen B, Rosvold O, et al. Paracetamol inhibits copper ion-induced, azo compound-initiated, and mononuclear cell-mediated oxidative modification of LDL. Arterioscler Thromb Vasc Biol. 1995;15(9):1338–1344.
   PubMed Web of Science ®Google Scholar
• Chou TM, Greenspan P. Effect of acetaminophen on the myeloperoxidase-hydrogen peroxide-nitrite mediated oxidation of LDL. Biochim Biophys Acta. 2002;15:1–2.
   Google Scholar
• Kapiotis S, Sengoelge G, Hermann M, et al. Paracetamol catalyzes myeloperoxidase-initiated lipid oxidation in LDL. Arterioscler Thromb Vasc Biol. 1997;17(11):2855–2860.
   PubMed Web of Science ®Google Scholar
• Ozsoy MB, Pabuçcuoğlu A. The effect of acetaminophen on oxidative modification of low-density lipoproteins in hypercholesterolemic rabbits. J Clin Biochem Nutr. 2007;41(1):27–31.
   PubMed Web of Science ®Google Scholar
• Zhang H, Jing X, Shi Y, et al. N-acetyl lysyltyrosylcysteine amide inhibits myeloperoxidase, a novel tripeptide inhibitor. J Lipid Res. 2013;54(11):3016–3029.
   PubMed Web of Science ®Google Scholar
• Yu G, Liang Y, Huang Z, et al. Inhibition of myeloperoxidase oxidant production by N-acetyl lysyltyrosylcysteine amide reduces brain damage in a murine model of stroke. J Neuroinflammation. 2016;13(1):016–0583.
   PubMedGoogle Scholar
• Yu G, Zheng S, Liang Y, et al. Inhibition of myeloperoxidase by N-acetyl lysyltyrosylcysteine amide reduces oxidative stress-mediated inflammation, neuronal damage, and neural stem cell injury in a murine model of stroke. J Pharmacol Exp Ther. 2018;364(2):311–322.
   PubMed Web of Science ®Google Scholar
• Shiba Y, Kinoshita T, Chuman H, et al. Flavonoids as substrates and inhibitors of myeloperoxidase: molecular actions of aglycone and metabolites. Chem Res Toxicol. 2008 Aug 01;21(8):1600–1609.
   PubMed Web of Science ®Google Scholar
• Zeka K, Ruparelia K, Arroo RRJ, et al. Flavonoids and their metabolites: prevention in cardiovascular diseases and diabetes. Diseases. 2017;5(3):19.
   Google Scholar
• Hertog MGL, Feskens EJM, Kromhout D, et al. Dietary antioxidant flavonoids and risk of coronary heart disease: the zutphen elderly study. Lancet. 1993 Oct 23;342(8878):1007–1011.
   PubMed Web of Science ®Google Scholar
• Kostyuk VA, Kraemer T, Sies H, et al. Myeloperoxidase/nitrite-mediated lipid peroxidation of low-density lipoprotein as modulated by flavonoids. FEBS Lett. 2003;537(1–3):146–150.
   PubMed Web of Science ®Google Scholar
• Loke WM, Proudfoot JM, McKinley AJ, et al. Quercetin and its in vivo metabolites inhibit neutrophil-mediated low-density lipoprotein oxidation. J Agric Food Chem. 2008 May 01;56(10):3609–3615.
   PubMed Web of Science ®Google Scholar
• Steffen Y, Schewe T, Sies H. Myeloperoxidase-mediated LDL oxidation and endothelial cell toxicity of oxidized LDL: attenuation by (−)-epicatechin. Free Radic Res. 2006 Jan 01;40(10):1076–1085.
   PubMed Web of Science ®Google Scholar
• Bhaskar S, Kumar KS, Krishnan K, et al. Quercetin alleviates hypercholesterolemic diet induced inflammation during progression and regression of atherosclerosis in rabbits. Nutrition. 2013 Jan 01;29(1):219–229.
   PubMed Web of Science ®Google Scholar
• Lu N, Sui Y, Tian R, et al. Inhibitive effects of quercetin on myeloperoxidase-dependent hypochlorous acid formation and vascular endothelial injury. J Agric Food Chem. 2018 May 16;66(19):4933–4940.
   PubMed Web of Science ®Google Scholar
• Taylor JC, Oey L. Ceruloplasmin: plasma inhibitor of the oxidative inactivation of alpha 1-protease inhibitor. Am Rev Respir Dis. 1982;126(3):476–482.
   PubMedGoogle Scholar
• Segelmark M, Persson B, Hellmark T, et al. Binding and inhibition of myeloperoxidase (MPO): a major function of ceruloplasmin? Clin Exp Immunol. 1997;108(1):167–174.
   PubMed Web of Science ®Google Scholar
• Chapman ALP, Mocatta TJ, Shiva S, et al. Ceruloplasmin is an endogenous inhibitor of myeloperoxidase. J Biol Chem. 2013;288(9):6465–6477.
   PubMed Web of Science ®Google Scholar
• Kennedy DJ, Weber ME, Wang X, et al. Abstract 19636: cardioprotective role of ceruloplasmin in heart failure via inhibition of myeloperoxidase activity. Circulation. 2014;130(suppl_2):A19636–A36.
   Google Scholar
• Morgan PE, Laura RP, Maki RA, et al. Thiocyanate supplementation decreases atherosclerotic plaque in mice expressing human myeloperoxidase. Free Radic Res. 2015;49(6):743–749.
   PubMed Web of Science ®Google Scholar
• Zietzer A, Niepmann ST, Camara B, et al. Sodium thiocyanate treatment attenuates atherosclerotic plaque formation and improves endothelial regeneration in mice. Plos One. 2019; 14(4):e0214476.
   PubMed Web of Science ®Google Scholar
• Kim CHJ, Mitchell JB, Bursill CA, et al. The nitroxide radical TEMPOL prevents obesity, hyperlipidaemia, elevation of inflammatory cytokines, and modulates atherosclerotic plaque composition in apoE−/− mice. Atherosclerosis. 2015 May 01;240(1):234–241.
   PubMed Web of Science ®Google Scholar